- Home
- SSL vs DNLI Comparison
SSL vs DNLI Comparison
Compare SSL & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSL
- DNLI
- Stock Information
- Founded
- SSL 1950
- DNLI 2013
- Country
- SSL South Africa
- DNLI United States
- Employees
- SSL N/A
- DNLI N/A
- Industry
- SSL Oil & Gas Production
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SSL Energy
- DNLI Health Care
- Exchange
- SSL Nasdaq
- DNLI Nasdaq
- Market Cap
- SSL 4.6B
- DNLI 4.5B
- IPO Year
- SSL N/A
- DNLI 2017
- Fundamental
- Price
- SSL $5.20
- DNLI $28.73
- Analyst Decision
- SSL
- DNLI Strong Buy
- Analyst Count
- SSL 0
- DNLI 11
- Target Price
- SSL N/A
- DNLI $38.90
- AVG Volume (30 Days)
- SSL 1.1M
- DNLI 718.4K
- Earning Date
- SSL 01-01-0001
- DNLI 11-06-2024
- Dividend Yield
- SSL 12.10%
- DNLI N/A
- EPS Growth
- SSL N/A
- DNLI N/A
- EPS
- SSL N/A
- DNLI N/A
- Revenue
- SSL $15,070,363,793.00
- DNLI N/A
- Revenue This Year
- SSL N/A
- DNLI N/A
- Revenue Next Year
- SSL $5.64
- DNLI $283.75
- P/E Ratio
- SSL N/A
- DNLI N/A
- Revenue Growth
- SSL N/A
- DNLI 204.74
- 52 Week Low
- SSL $5.14
- DNLI $14.56
- 52 Week High
- SSL $12.58
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- SSL 30.15
- DNLI 57.14
- Support Level
- SSL $5.30
- DNLI $26.17
- Resistance Level
- SSL $5.45
- DNLI $33.33
- Average True Range (ATR)
- SSL 0.12
- DNLI 1.46
- MACD
- SSL -0.03
- DNLI 0.36
- Stochastic Oscillator
- SSL 4.13
- DNLI 52.44
About SSL Sasol Ltd.
Sasol Ltd operates as a vertically integrated chemicals and energy company through its two main segments: Energy business and Chemical business. It generates maximum revenue from the Chemicals segment. The company operates coal mines and its upstream interests in oil and gas, both of which are used as feedstock in the company's energy and chemicals operations. Sasol markets commodity and performance chemicals, sells liquid fuel products, and markets, distributes and transports pipeline gas. Geographically the company generates the majority of its revenue from South Africa.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.